8月19日 - ** 药物开发商Celldex Therapeutics CLDX.O股价盘后下跌15%至20.42美元
** 该公司称 (link)，将不会推进其实验性药物巴唑波利单抗（barzolvolimab）在嗜酸性粒细胞性食管炎（一种慢性食管炎症性疾病）中的开发。
** 在一项中期研究中，该药物达到了主要目标，表明它能有效消耗胃肠道中的肥大细胞，但与安慰剂相比，症状没有得到改善
** 公司将继续研究用于其他皮肤病的巴唑伐利单抗
** 股价今年以来下跌 ~5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.